Therapeutic Asset Ratings
423 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
cm518d1
Cancer
Keymed Biosciences Co.Ltd
P1/2
CC
(40)
cs2009
Cancer
CStone Pharmaceuticals
P1/2
CC
(40)
Dalmitamig
Cancer
Regeneron Pharmaceuticals
P1/2
CC
(40)
DALPICICLIB ISETIONATE
Cancer
Risen (Suzhou) Pharma Tech Co., Ltd.
P1/2
CC
(40)
db-1311
Cancer
DualityBio Inc.
P1/2
CC
(40)
dt-7012
Cancer
Domain Therapeutics Australia Pty Ltd
P1/2
CC
(40)
Duvelisib
Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
P1/2
CC
(40)
Eb-Nk-301
Cancer
Beijing Biotech
P1/2
CC
(40)
eik1004-001
Cancer
Eikon Therapeutics
P1/2
CC
(40)
eik1005
Cancer
Eikon Therapeutics
P1/2
CC
(40)
ETX-636
Cancer
Ensem Therapeutics
P1/2
CC
(40)
fl115
Cancer
Suzhou Forlong Biotechnology Co., Ltd
P1/2
CC
(40)
gfh375
Cancer
Genfleet Therapeutics (Shanghai) Inc.
P1/2
CC
(40)
Gic-102
Cancer
GI Cell, Inc.
P1/2
CC
(40)
gw5282
Cancer
Dizal Pharmaceuticals
P1/2
CC
(40)
her2bbζ/cd19t+ t cells
Cancer
T-knife GmbH
P1/2
CC
(40)
hrs2398
Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.
P1/2
CC
(40)
Hrs-4642
Cancer
Jiangsu HengRui Medicine Co., Ltd.
P1/2
CC
(40)
Hrs-6768
Cancer
Jiangsu HengRui Medicine Co., Ltd.
P1/2
CC
(40)
hsk39775 monotherapy
Cancer
Xizang Haisco Pharmaceutical Co., Ltd
P1/2
CC
(40)
Idov-Safetm
Advanced Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P1/2
CC
(40)
imm01
Cancer
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
P1/2
CC
(40)
Immunoglobulin G1 [de-448-lysine], anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 ?1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human epidermal growth factor receptor HER3) (human clone HER3.H3 single-chain variable fragment VH-(GGGGS)3-VL), complex with human-mouse monoclonal C225 ?-chain, dimer, 214??,214???,222,222?,228,228?,231,231?-octakis(thioether) with (2S)-N-(carboxymethyl)-2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-?-alanylglycylglycyl-L-phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1-methyl-2-oxoethoxy]methyl]glycinamide
Advanced Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P1/2
CC
(40)
immunoglobulin G1-kappa, anti-[Homo sapiens ERBB2 (receptor tyrosine-protein kinase erbB-2, epidermal growth factor receptor 2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], humanized monoclonal antibody, conjugated at glutaminyl residues to monomethylauristatin E (MMAE), with a ratio of 1 to 2, via a cleavable linker
Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
P1/2
CC
(40)
Immunoglobulin G4 [221-proline], anti-(human programmed cell death protein 1) (human monoclonal SG001 ?4-chain), disulfide with human monoclonal SG001 ?-chain, dimer
Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.
P1/2
CC
(40)
Showing 126 to 150 of 423 assets
Previous
Page 6 of 17
Next
